Last reviewed · How we verify
NCT06215950
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer
Phase 1 trial testing CD70 CAR-T cells in Ovarian Cancer in 36 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Chongqing Precision Biotech Co., Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 10 January 2024 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- CD70 CAR-T cells
- CD70 CAR-T cells
Conditions studied
- Ovarian Cancer — all drugs for Ovarian Cancer →
- Cervix Cancer — all drugs for Cervix Cancer →
- Metastatic Cancer — all drugs for Metastatic Cancer →
- Advanced Cancer — all drugs for Advanced Cancer →
Sponsor
Chongqing Precision Biotech Co., Ltd — full company profile →
Who can join
18 and older, any sex, with Ovarian Cancer or Cervix Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic Gynecologic Cancer, and obtain recommended doses and infusion patterns.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects.
Qin H, Zhou Z, Shi R, Mai Y, et al · · 2025 · cited 15× · PMID 40483473 · DOI 10.1186/s13045-025-01701-6 -
Advances and obstacles of T cell-based immunotherapy in gynecological malignancies.
Zhao X, Ran J, Li S, Chen J. · · 2025 · cited 14× · PMID 40713697 · DOI 10.1186/s12943-025-02411-w -
Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions.
Rafii S, Mukherji D, Komaranchath AS, Khalil C, et al · · 2025 · cited 6× · PMID 40940995 · DOI 10.3390/cancers17172898 -
CAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead.
Al Shaer NSH, Masoud I, Tleyjeh A, Al-Attas AA, et al · · 2026 · PMID 41993194 · DOI 10.3389/fimmu.2026.1796675 -
Stem cell engineering for the generation of allogeneic CAR-directed natural killer T cells targeting endometrial carcinoma.
Li YR, DiBernardo GA, Chen Y, Shen X, et al · · 2026 · PMID 41612507 · DOI 10.1186/s40164-026-00746-8 -
N-Acetyl Cysteine as a promising therapeutic approach in ovarian cancer: potential and perspectives.
Kindlon EA, Pidgeon GP. · · 2025 · PMID 40642398 · DOI 10.20935/acadonco7784
Verify or expand the search:
- PubMed search for NCT06215950
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CD70 CAR-T cells
Trials testing the same drug.
- NCT06010875 — A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors · Phase 1 · recruiting
- NCT05468190 — A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T · Phase 1 · unknown
- NCT05518253 — A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors · Phase 1 · recruiting
- NCT05420545 — A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors · Phase 1 · unknown
- NCT05420519 — Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer · Phase 1 · unknown
Other recruiting trials for Ovarian Cancer
Currently open trials in the same condition.
- NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
- NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
- NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
- NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Chongqing Precision Biotech Co., Ltd trials
Trials by the same sponsor.
- NCT07181720 — CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors · Phase 1 · recruiting
- NCT07179692 — CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors · Phase 1 · recruiting
- NCT07184450 — Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases · Phase 1 · recruiting
- NCT07239323 — In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies · Phase 1 · recruiting
- NCT06892145 — Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06215950 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chongqing Precision Biotech Co., Ltd
- Last refreshed: 22 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06215950.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing